Current Oncology Reports

, Volume 15, Issue 4, pp 347–355

Vascular Sarcomas

Sarcomas (SR Patel, Section Editor)


Vascular sarcomas are soft-tissue tumors that arise from the endothelium with a malignant potential. This review discusses the management of epithelioid hemangioendothelioma (EHE) and angiosarcoma. EHE is a vascular tumor of intermediate malignant potential with an indolent course. EHE arising from the liver, lung, or bone tends to be multifocal and the rate of progression is slow and often unpredictable. Treatment should be considered in patients with significant symptomatic deterioration and/or progressive disease on imaging studies. Various cytotoxic and targeted therapies are available for management, with disease stabilization as the most common outcome. Angiosarcoma is an aggressive vascular tumor with a high malignant potential. Multidisciplinary care is critical for the management of localized disease, and the best outcomes are often observed in patients when a combination of systemic and local therapy options is used. Metastatic angiosarcoma is treated primarily with systemic therapy, and several cytotoxic and targeted therapies are available, alone or in combination. The choice of therapy depends on several factors, such as cutaneous location of the tumor, performance status of the patient, toxicity of the treatment, and patient goals.


Epithelioid hemangioendothelioma Angiosarcoma Vascular tumors Vascular sarcomas Vascular sarcoma Angiosarcoma treatment Bevacizumab Sorafenib Sunitinib Orally administered cyclophosphamide Pazopanib Paclitaxel Gemcitabine Docetaxel Adriamycin Doxorubicin Ifosfamide 


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Cancer. 1982;50:970–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Mentzel T, Beham A, Calonje E, Katenkamp D, Fletcher CD. Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases. Am J Surg Pathol. 1997;21:363–74.PubMedCrossRefGoogle Scholar
  3. 3.
    Kleer CG, Unni KK, McLeod RA. Epithelioid hemangioendothelioma of bone. Am J Surg Pathol. 1996;20:1301–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Makhlouf HR, Ishak KG, Goodman ZD. Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer. 1999;85:562–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Mehrabi A, Kashfi A, Fonouni H, et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer. 2006;107:2108–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Weiss SW, Goldblum JR. Hemangioendothelioma: vascular tumors of intermediate malignancy. In: Enzinger and Weiss's soft tissue tumors. 5th ed. Philadelphia: Mosby; 2008. p. 681–702.Google Scholar
  7. 7.
    Bhagavan BS, Dorfman HD, Murthy MS, Eggleston JC. Intravascular bronchiolo-alveolar tumor (IVBAT): A low-grade sclerosing epithelioid angiosarcoma of lung. Am J Surg Pathol. 1982;6:41–52.PubMedCrossRefGoogle Scholar
  8. 8.
    Marino IR, Todo S, Tzakis AG, et al. Treatment of hepatic epithelioid hemangioendothelioma with liver transplantation. Cancer. 1988;62:2079–84.PubMedCrossRefGoogle Scholar
  9. 9.
    Kelleher MB, Iwatsuki S, Sheahan DG. Epithelioid hemangioendothelioma of liver. Clinicopathological correlation of 10 cases treated by orthotopic liver transplantation. Am J Surg Pathol. 1989;13:999–1008.PubMedCrossRefGoogle Scholar
  10. 10.
    Ben-Haim M, Roayaie S, Ye MQ, et al. Hepatic epithelioid hemangioendothelioma: resection or transplantation, which and when? Liver Transpl Surg. 1999;5:526–31.PubMedCrossRefGoogle Scholar
  11. 11.
    Yokoyama I, Todo S, Iwatsuki S, Starzl TE. Liver transplantation in the treatment of primary liver cancer. Hepatogastroenterology. 1990;37:188–93.PubMedGoogle Scholar
  12. 12.
    Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery. 1991;110:726–34. discussion 734-5.PubMedGoogle Scholar
  13. 13.
    Pichlmayr R, Weimann A, Ringe B. Indications for liver transplantation in hepatobiliary malignancy. Hepatology. 1994;20:33S–40S.PubMedGoogle Scholar
  14. 14.
    Madariaga JR, Marino IR, Karavias DD, et al. Long-term results after liver transplantation for primary hepatic epithelioid hemangioendothelioma. Ann Surg Oncol. 1995;2:483–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Furui S, Itai Y, Ohtomo K, et al. Hepatic epithelioid hemangioendothelioma: report of five cases. Radiology. 1989;171:63–8.PubMedGoogle Scholar
  16. 16.
    Holley MP, Cuschieri A. Epithelioid haemangioendothelioma of the liver: objective response to hepatic intra-arterial 5-FU. Eur J Surg Oncol. 1989;15:73–8.PubMedGoogle Scholar
  17. 17.
    Idilman R, Dokmeci A, Beyler AR, et al. Successful medical treatment of an epithelioid hemangioendothelioma of liver. Oncology. 1997;54:171–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Gambacorta M, Bonacina E. Epithelioid hemangioendothelioma: report of a case diagnosed by fine-needle aspiration. Diagn Cytopathol. 1989;5:207–10.PubMedCrossRefGoogle Scholar
  19. 19.
    Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24:257–63.PubMedCrossRefGoogle Scholar
  20. 20.
    • Chevreau C, Le Cesne A, Ray-Coquard I, Italiano A, Cioffi A, Isambert N, et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer. 2013;119:2639–44. Largest prospective clinical trial in EHE using a targeted therapy.Google Scholar
  21. 21.
    Kayler LK, Merion RM, Arenas JD, et al. Epithelioid hemangioendothelioma of the liver disseminated to the peritoneum treated with liver transplantation and interferon alpha-2B. Transplantation. 2002;74:128–30.PubMedCrossRefGoogle Scholar
  22. 22.
    Mascarenhas RC, Sanghvi AN, Friedlander L, Geyer SJ, Beasley HS, Van Thiel DH. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology. 2004;67:471–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Sumrall A, Fredericks R, Berthold A, Shumaker G. Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease. J Neurooncol. 2010;97:275–7.Google Scholar
  24. 24.
    Otrock ZK, Al-Kutoubi A, Kattar MM, Zaatari G, Soweid A. Spontaneous complete regression of hepatic epithelioid haemangioendothelioma. Lancet Oncol. 2006;7:439–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Weiss SW, Goldblum JR. Malignant vascular tumors. In: Enzinger and Weiss's soft tissue tumors. 5th ed. Philadelphia: Mosby; 2008. p. 703–32.Google Scholar
  26. 26.
    Offori TW, Platt CC, Stephens M, Hopkinson GB. Angiosarcoma in congenital hereditary lymphoedema (Milroy's disease)—diagnostic beacons and a review of the literature. Clin Exp Dermatol. 1993;18:174–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Qureshi YA, Strauss DC, Thway K, Fisher C, Thomas JM. Angiosarcoma developing in a non-functioning arteriovenous fistula post-renal transplant. J Surg Oncol. 2010;101:520–3.Google Scholar
  28. 28.
    O'Connor JP, Quinn J, Wall D, Petrie JJ, Hardie JR, Woodruff PW. Cutaneous angiosarcoma following graft irradiation in a renal transplant patient. Clin Nephrol. 1986;25:54–5.PubMedGoogle Scholar
  29. 29.
    Conlon PJ, Daly T, Doyle G, Carmody M. Angiosarcoma at the site of a ligated arteriovenous fistula in a renal transplant recipient. Nephrol Dial Transplant. 1993;8:259–62.PubMedGoogle Scholar
  30. 30.
    Keane MM, Carney DN. Angiosarcoma arising from a defunctionalized arteriovenous fistula. J Urol. 1993;149:364–5.PubMedGoogle Scholar
  31. 31.
    Parrott NR, Scott PD, Freemont AJ, Johnson RW. Angiosarcoma in an arteriovenous fistula following successful renal transplantation—a case report. Transplantation. 1993;55:676–7.PubMedGoogle Scholar
  32. 32.
    Byers RJ, McMahon RF, Freemont AJ, Parrott NR, Newstead CS. Angiosarcoma at the site of a ligated arteriovenous fistula in a renal transplant recipient. Nephrol Dial Transplant. 1994;9:112.PubMedGoogle Scholar
  33. 33.
    Dargent JL, Vermylen P, Abramowicz D, et al. Disseminated angiosarcoma presenting as a hemophagocytic syndrome in a renal allograft recipient. Transpl Int. 1997;10:61–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Kibe Y, Kishimoto S, Katoh N, Yasuno H, Yasumura T, Oka T. Angiosarcoma of the scalp associated with renal transplantation. Br J Dermatol. 1997;136:752–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Bessis D, Sotto A, Roubert P, Chabrier PE, Mourad G, Guilhou JJ. Endothelin-secreting angiosarcoma occurring at the site of an arteriovenous fistula for haemodialysis in a renal transplant recipient. Br J Dermatol. 1998;138:361–3.PubMedCrossRefGoogle Scholar
  36. 36.
    Wehrli BM, Janzen DL, Shokeir O, Masri BA, Byrne SK, O'Connell JX. Epithelioid angiosarcoma arising in a surgically constructed arteriovenous fistula: a rare complication of chronic immunosuppression in the setting of renal transplantation. Am J Surg Pathol. 1998;22:1154–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Ahmed I, Hamacher KL. Angiosarcoma in a chronically immunosuppressed renal transplant recipient: report of a case and review of the literature. Am J Dermatopathol. 2002;24:330–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Farag R, Schulak JA, Abdul-Karim FW, Wasman JK. Angiosarcoma arising in an arteriovenous fistula site in a renal transplant patient: a case report and literature review. Clin Nephrol. 2005;63:408–12.PubMedGoogle Scholar
  39. 39.
    Sanchez EQ, Marubashi S, Jung G, et al. De novo tumors after liver transplantation: a single-institution experience. Liver Transpl. 2002;8:285–91.PubMedCrossRefGoogle Scholar
  40. 40.
    Johnson KH, Ghobrial HK, Buoen LC, Brand I, Brand KG. Nonfibroblastic origin of foreign body sarcomas implicated by histological and electron microscopic studies. Cancer Res. 1973;33:3139–54.PubMedGoogle Scholar
  41. 41.
    Hayman J, Huygens H. Angiosarcoma developing around a foreign body. J Clin Pathol. 1983;36:515–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Jennings TA, Peterson L, Axiotis CA, Friedlaender GE, Cooke RA, Rosai J. Angiosarcoma associated with foreign body material. A report of three cases. Cancer. 1988;62:2436–44.PubMedCrossRefGoogle Scholar
  43. 43.
    Ben-Izhak O, Kerner H, Brenner B, Lichtig C. Angiosarcoma of the colon developing in a capsule of a foreign body. Report of a case with associated hemorrhagic diathesis. Am J Clin Pathol. 1992;97:416–20.PubMedGoogle Scholar
  44. 44.
    Ravi R. Primary angiosarcoma of the urinary bladder. Arch Esp Urol. 1993;46:351–3.PubMedGoogle Scholar
  45. 45.
    Schneider T, Renney J, Hayman J. Angiosarcoma occurring with chronic osteomyelitis and residual foreign material: case report of a late World War II wound complication. Aust N Z J Surg. 1997;67:576–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Ben-Izhak O, Vlodavsky E, Ofer A, Engel A, Nitecky S, Hoffman A. Epithelioid angiosarcoma associated with a Dacron vascular graft. Am J Surg Pathol. 1999;23:1418–22.PubMedCrossRefGoogle Scholar
  47. 47.
    Cokelaere K, Vanvuchelen J, Michielsen P, Sciot R. Epithelioid angiosarcoma of the splenic capsule. Report of a case reiterating the concept of inert foreign body tumorigenesis. Virchows Arch. 2001;438:398–403.PubMedCrossRefGoogle Scholar
  48. 48.
    Keymeulen K, Dillemans B. Epitheloid angiosarcoma of the splenic capsula as a result of foreign body tumorigenesis. A case report. Acta Chir Belg. 2004;104:217–20.PubMedGoogle Scholar
  49. 49.
    Mallick A, Jain S, Proctor A, Pandey R. Angiosarcoma around a revision total hip arthroplasty and review of literature. J Arthroplasty. 2009;24:323 e17–20.CrossRefGoogle Scholar
  50. 50.
    Bach AD, Walgenbach KJ, Horch RE. Hemangiosarcoma of the left hand in a patient with the rare combination of Maffucci's and Stewart Treves syndrome. Vasa. 2000;29:71–3.PubMedCrossRefGoogle Scholar
  51. 51.
    Davidson TI, Kissin MW, Bradish CF, Westbury G. Angiosarcoma arising in a patient with Maffucci syndrome. Eur J Surg Oncol. 1985;11:381–4.PubMedGoogle Scholar
  52. 52.
    Lennox EL, Draper GJ, Sanders BM. Retinoblastoma: a study of natural history and prognosis of 268 cases. Br Med J. 1975;3:731–4.PubMedCrossRefGoogle Scholar
  53. 53.
    Dunkel IJ, Gerald WL, Rosenfield NS, Strong EW, Abramson DH, Ghavimi F. Outcome of patients with a history of bilateral retinoblastoma treated for a second malignancy: the Memorial Sloan-Kettering experience. Med Pediatr Oncol. 1998;30:59–62.PubMedCrossRefGoogle Scholar
  54. 54.
    De Silva BD, Nawroz I, Doherty VR. Angiosarcoma of the head and neck associated with xeroderma pigmentosum variant. Br J Dermatol. 1999;141:166–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Leake J, Sheehan MP, Rampling D, Ramani P, Atherton DJ. Angiosarcoma complicating xeroderma pigmentosum. Histopathology. 1992;21:179–81.PubMedCrossRefGoogle Scholar
  56. 56.
    Arora R, Sharma A, Gupta R, Vijayaraghavan M. Cutaneous angiosarcoma in a patient with xeroderma pigmentosum. Indian J Pathol Microbiol. 2008;51:504–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Marcon I, Collini P, Casanova M, Meazza C, Ferrari A. Cutaneous angiosarcoma in a patient with xeroderma pigmentosum. Pediatr Hematol Oncol. 2004;21:23–6.PubMedGoogle Scholar
  58. 58.
    Ploegmakers MJ, Pruszczynski M, De Rooy J, Kusters B, Veth RP. Angiosarcoma with malignant peripheral nerve sheath tumour developing in a patient with Klippel-Trenaunay-Weber syndrome. Sarcoma. 2005;9:137–40.PubMedCrossRefGoogle Scholar
  59. 59.
    Millstein DI, Tang CK, Campbell Jr EW. Angiosarcoma developing in a patient with Neurofibromatosis (von Recklinghausen's disease). Cancer. 1981;47:950–4.PubMedCrossRefGoogle Scholar
  60. 60.
    Riccardi VM, Wheeler TM, Pickard LR, King B. The pathophysiology of neurofibromatosis. II. Angiosarcoma as a complication. Cancer Genet Cytogenet. 1984;12:275–80.PubMedCrossRefGoogle Scholar
  61. 61.
    Lederman SM, Martin EC, Laffey KT, Lefkowitch JH. Hepatic neurofibromatosis, malignant schwannoma, and angiosarcoma in von Recklinghausen's disease. Gastroenterology. 1987;92:234–9.PubMedGoogle Scholar
  62. 62.
    Brown RW, Tornos C, Evans HL. Angiosarcoma arising from malignant schwannoma in a patient with neurofibromatosis. Cancer. 1992;70:1141–4.PubMedCrossRefGoogle Scholar
  63. 63.
    Png MA, Teh HS, Poh WT. Case report: angiosarcoma in a patient with von Recklinghausen's disease. Clin Radiol. 1996;51:521–3.PubMedCrossRefGoogle Scholar
  64. 64.
    Sakaguchi N, Sano K, Ito M, Baba T, Fukuzawa M, Hotchi M. A case of von Recklinghausen's disease with bilateral pheochromocytoma-malignant peripheral nerve sheath tumors of the adrenal and gastrointestinal autonomic nerve tumors. Am J Surg Pathol. 1996;20:889–97.PubMedCrossRefGoogle Scholar
  65. 65.
    Andreu V, Elizalde I, Mallafre C, et al. Plexiform neurofibromatosis and angiosarcoma of the liver in von Recklinghausen disease. Am J Gastroenterol. 1997;92:1229–30.PubMedGoogle Scholar
  66. 66.
    Elli M, Can B, Ceyhan M, et al. Intrathoracic malignant peripheral nerve sheath tumor with angiosarcoma in a child with NF1. Tumori. 2007;93:641–4.PubMedGoogle Scholar
  67. 67.
    Morphopoulos GD, Banerjee SS, Ali HH, et al. Malignant peripheral nerve sheath tumour with vascular differentiation: a report of four cases. Histopathology. 1996;28:401–10.PubMedGoogle Scholar
  68. 68.
    Mentzel T, Katenkamp D. Intraneural angiosarcoma and angiosarcoma arising in benign and malignant peripheral nerve sheath tumours: clinicopathological and immunohistochemical analysis of four cases. Histopathology. 1999;35:114–20.PubMedCrossRefGoogle Scholar
  69. 69.
    McMenamin ME, Fletcher CD. Expanding the spectrum of malignant change in schwannomas: epithelioid malignant change, epithelioid malignant peripheral nerve sheath tumor, and epithelioid angiosarcoma: a study of 17 cases. Am J Surg Pathol. 2001;25:13–25.PubMedCrossRefGoogle Scholar
  70. 70.
    Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11:241–7.PubMedCrossRefGoogle Scholar
  71. 71.
    White CW, Wolf SJ, Korones DN, Sondheimer HM, Tosi MF, Yu A. Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. J Pediatr. 1991;118:59–66.PubMedCrossRefGoogle Scholar
  72. 72.
    Torres KE, Ravi V, Kin K, et al. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol. 2013;20:1267–74.PubMedCrossRefGoogle Scholar
  73. 73.
    Guadagnolo BA, Zagars GK, Araujo D, Ravi V, Shellenberger TD, Sturgis EM. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck. 2011;33:661–7.PubMedCrossRefGoogle Scholar
  74. 74.
    Candeias CM, Luis I, Ribeiro J, et al. Extended remission of metastatic epithelioid angiosarcoma of the heart with liposomal doxorubicin. BMJ Case Rep. 2010;2010.Google Scholar
  75. 75.
    Eiling S, Lischner S, Busch JO, Rothaupt D, Christophers E, Hauschild A. Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. Br J Dermatol. 2002;147:150–3.PubMedCrossRefGoogle Scholar
  76. 76.
    Holloway CL, Turner AR, Dundas GS. Cutaneous angiosarcoma of the scalp: a case report of sustained complete response following liposomal Doxorubicin and radiation therapy. Sarcoma. 2005;9:29–31.PubMedCrossRefGoogle Scholar
  77. 77.
    Wollina U, Fuller J, Graefe T, Kaatz M, Lopatta E. Angiosarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy. J Cancer Res Clin Oncol. 2001;127:396–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Italiano A, Cioffi A, Penel N, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2012;118:3330–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005;104:361–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Waldmann V. Liposomal doxorubicin in the treatment of metastasized angiosarcoma. Br J Dermatol. 2003;148:606.PubMedCrossRefGoogle Scholar
  81. 81.
    Casper ES, Waltzman RJ, Schwartz GK, et al. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest. 1998;16:442–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034–7.PubMedCrossRefGoogle Scholar
  83. 83.
    Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26:5269–74.PubMedCrossRefGoogle Scholar
  84. 84.
    Stacchiotti S, Palassini E, Sanfilippo R, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol. 2012;23:501–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Anderson SE, Keohan ML, D'Adamo DR, Maki RG. A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma. 2006;2006:15947.PubMedCrossRefGoogle Scholar
  86. 86.
    Penel N, Italiano A, Ray-Coquard I, et al. Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol. 2012;23:517–23.PubMedCrossRefGoogle Scholar
  87. 87.
    Arnaout A, Wedman DM, El-Sayed S, Acharya V, Lad S. Neoadjuvant gemcitabine-taxane chemotherapy for radiation-induced angiosarcoma of the breast: a case report. Breast J. 2012;18:276–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Shkoukani MA, Carron MA, Tulunay O, Kucuk O, Lin HS. Angiosarcoma of the scalp with complete response to a biweekly gemcitabine and docetaxel (GEMDOC) chemotherapy regimen. Ear Nose Throat J. 2011;90:E26–9.PubMedGoogle Scholar
  89. 89.
    Wilson R, Glaros S, Brown RK, Michael C, Reisman D. Complete radiographic response of primary pulmonary angiosarcomas following gemcitabine and taxotere. Lung Cancer. 2008;61:131–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Lu HJ, Chen PC, Yen CC, et al. Refractory cutaneous angiosarcoma successfully treated with sunitinib. Br J Dermatol. 2013. doi:10.1111/bjd.12258.Google Scholar
  91. 91.
    Yoo C, Kim JE, Yoon SK, et al. Angiosarcoma of the retroperitoneum: report on a patient treated with sunitinib. Sarcoma. 2009;2009:360875.PubMedCrossRefGoogle Scholar
  92. 92.
    • Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133–40. Prospective clinical trial for targeted therapy in angiosarcoma using antiangiogenic agents.Google Scholar
  93. 93.
    Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996;77:2400–6.PubMedCrossRefGoogle Scholar
  94. 94.
    Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18:2030–6.PubMedCrossRefGoogle Scholar
  95. 95.
    Woodward AH, Ivins JC, Soule EH. Lymphangiosarcoma arising in chronic lymphedematous extremities. Cancer. 1972;30:562–72.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Sarcoma Medical OncologyUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations